Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Phase 3

Completed

Conditions: Meningitis, Meningococcal

Interventions: Biological: control
Biological: rLP2086 vaccine

First Posted Date: 2011-05-12

Last Posted Date: 2015-03-11

Lead Sponsor: Pfizer

Target Recruit Count: 5715

Registration Number: NCT01352793

Locations: 🇺🇸
Clinical Research Advantage, Inc. / East Valley Family Physicians, PLC, Tempe, Arizona, United States
🇺🇸
Clinical Research Advantage, Inc./Prairie Fields Family Medicine, PC Administrative/Mailing Address, Tempe, Arizona, United States
🇺🇸
Optimal Research, LLC, Melbourne, Florida, United States

and more 74 locations

Single Dose Study To Compare Pharmacokinietics Of 3 Different Formulations Of PF-04991532 In Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Formulation 3
Drug: Formulation 2
Drug: Formulation 1

First Posted Date: 2011-05-10

Last Posted Date: 2011-07-06

Lead Sponsor: Pfizer

Target Recruit Count: 12

Registration Number: NCT01351129

Locations: 🇸🇬
Pfizer Investigational Site, Singapore, Singapore

A Bioequivalence Study Of Ibuprofen 50mg/ml (laboratórios Pfizer Ltda) In The Oral Suspension Form.

Phase 4

Completed

Conditions: Healthy

Interventions: Drug: Alivium®
Drug: Ibuprofen

First Posted Date: 2011-05-10

Last Posted Date: 2011-08-03

Lead Sponsor: Pfizer

Target Recruit Count: 24

Registration Number: NCT01350596

Locations: 🇧🇷
Pfizer Investigational Site, Aparecida de Goiania, Goias, Brazil

A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Phase 2

Completed

Conditions: Hypercholesterolemia
Dyslipidemia

Interventions: Other: Placebo
Drug: PF-04950615 (RN316)

First Posted Date: 2011-05-09

Last Posted Date: 2017-11-08

Lead Sponsor: Pfizer

Target Recruit Count: 46

Registration Number: NCT01350141

Locations: 🇺🇸
Atlanta Diabetes Associates, Atlanta, Georgia, United States
🇺🇸
Wake Research Associates, LLC, Raleigh, North Carolina, United States
🇺🇸
Kendall South Medical Center, Inc., Miami, Florida, United States

and more 32 locations

Clinical Study Of PI3K/mTOR Inhibitors In Combination With An Oral MEK Inhibitor Or Irinotecan In Patients With Advanced Cancer

Phase 1

Terminated

Conditions: Advanced Cancer

Interventions: Drug: PF-05212384
Drug: PD-0325901
Drug: irinotecan

First Posted Date: 2011-05-04

Last Posted Date: 2018-10-29

Lead Sponsor: Pfizer

Target Recruit Count: 105

Registration Number: NCT01347866

Locations: 🇺🇸
Ronald Reagan UCLA Medical Center, Los Angeles, California, United States
🇺🇸
UCLA Oncology Center, Los Angeles, California, United States
🇨🇦
Princess Margaret Hospital, Toronto, Ontario, Canada

and more 14 locations

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

Phase 2

Completed

Conditions: Reduction in Hypertrophic Skin Scarring

Interventions: Drug: EXC 001

First Posted Date: 2011-05-04

Last Posted Date: 2021-09-09

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT01346969

Locations: 🇺🇸
Bayside Ambulatory Center, Miami, Florida, United States
🇺🇸
Endeavor Clinical Trials,P.A., San Antonio, Texas, United States
🇺🇸
Aesthetic Plastic Surgery Miami, Miami, Florida, United States

and more 9 locations

Assessment Of The Effects Of Single Doses Of An Investigational Drug, Given Alone Or With Donepezil, On Scopolamine-Induced Changes In Memory And Learning In Healthy Adults

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Scopolamine + Donepezil Placebo + PF-04995274 Placebo
Drug: Scopolamine + Donepezil 5 mg + PF-04995274 Placebo
Drug: Scopolamine + Donepezil 10mg + PF-04995274 Placebo
Drug: Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg
Drug: Scopolamine + Donepezil Placebo + PF-04995274 15 mg

First Posted Date: 2011-05-02

Last Posted Date: 2011-11-17

Lead Sponsor: Pfizer

Target Recruit Count: 88

Registration Number: NCT01345864

Locations: 🇺🇸
Pfizer Investigational Site, New Haven, Connecticut, United States

B0151005 Open-Label Extension Study

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Biological: PF-04236921

First Posted Date: 2011-05-02

Last Posted Date: 2024-01-12

Lead Sponsor: Pfizer

Target Recruit Count: 191

Registration Number: NCT01345318

Locations: 🇨🇿
Fakultni nemocnice Olomouc, Olomouc, Czechia
🇧🇷
Hospital Israelita Albert Einstein, São Paulo, SP, Brazil
🇨🇿
Fakultni Nemocnice Kralovske Vinohrady, Praha 10, Czechia

and more 124 locations

A Multiple Dose Study of PF-04950615 (RN316) in Subjects on High Doses of Statins

Phase 2

Completed

Conditions: Hypercholesterolemia
Dyslipidemia

Interventions: Biological: Placebo
Biological: PF-04950615 (RN316)
Drug: Statin
Drug: Satin

First Posted Date: 2011-04-27

Last Posted Date: 2017-10-11

Lead Sponsor: Pfizer

Target Recruit Count: 93

Registration Number: NCT01342211

Locations: 🇺🇸
Kendall South Medical Center, Miami, Florida, United States
🇺🇸
Texas Center for Drug Development, Inc., Houston, Texas, United States
🇺🇸
Heartland Research Associates, LLC, Wichita, Kansas, United States

and more 41 locations

Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2.

Completed

Conditions: Renal Cell Carcinoma

Interventions: Other: Non-interventional

First Posted Date: 2011-04-21

Last Posted Date: 2014-08-18

Lead Sponsor: Pfizer

Target Recruit Count: 1073

Registration Number: NCT01339962

Locations: 🇩🇰
University of Copenhagen Herlev Hospital, Herlev, Denmark

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy